FDA clears Crescent Biopharma IND for CR-002 solid tumor ADC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to FDA clears Crescent Biopharma IND for CR-002 solid tumor ADC

Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors

October 5, 2026 7:30 AM EDT

Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to initiate in the fourth quarter of 2026

Initial clinical data expected in the second half of 2027

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) --  Crescent Biopharma, Inc. (Crescent or the Company) (Nasdaq:... More